Soleno Therapeutics (SLNO) Receives a Buy From Stifel Nicolaus
Express News | Soleno Therapeutics Inc : Stifel Cuts Target Price to $59 From $63
Baird Starts Soleno Therapeutics With Outperform Rating, $72 Price Target
Soleno Therapeutics (SLNO) has an average rating of buy and price targets ranging from $59 to $93, according to analysts polled by Capital IQ.
Express News | Soleno Therapeutics Inc : Guggenheim Raises Target Price to $61 From $51
Soleno Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/10/2024 50.22% Baird → $72 Initiates Coverage On → Outperform 02/05/2024 94.03% Piper Sandler → $93 Ini
Express News | Soleno Therapeutics Inc : Baird Initiates Coverage With Outperform Rating; Target Price $72
Express News | Soleno Therapeutics Q1 2024 Adj EPS $(0.59) Misses $(0.37) Estimate
Soleno Therapeutics | 10-Q: Quarterly report
Soleno Therapeutics' DCCR Poised for FDA Approval and Blockbuster Sales: An Analyst's Bullish Outlook
Soleno Therapeutics 1Q Loss $21.4M >SLNO
Soleno Therapeutics 1Q Loss $21.4M >SLNO
Soleno Therapeutics Prices $138 Million Stock Offering
Soleno Therapeutics (SLNO) said late Thursday it priced an underwritten public offering of 3 million common shares at $46 per share for expected gross proceeds of $138 million. The underwriters have b
Soleno to Use Proceeds to Fund R&D on Lead Product Candidate >SLNO
Soleno to Use Proceeds to Fund R&D on Lead Product Candidate >SLNO
Soleno Has Granted Underwriters Option to Purchase Up to 450,000 Shares >SLNO
Soleno Has Granted Underwriters Option to Purchase Up to 450,000 Shares >SLNO
Piper Sandler, Guggenheim Securities Among Managers for Soleno Offfering >SLNO
Piper Sandler, Guggenheim Securities Among Managers for Soleno Offfering >SLNO
Soleno Offering Is Expected to Close on or About May 7 >SLNO
Soleno Offering Is Expected to Close on or About May 7 >SLNO
Express News | Soleno Therapeutics Inc - Pricing of Underwritten Public Offering of 3 Mln Shares of Its Common Stock at a Public Offering Price of $46.00 per Share
Express News | Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering of Common Stock
Express News | Soleno Therapeutics Announces Proposed Public Offering of Common Stock
Soleno Therapeutics(SLNO.US) 10% Shareholder Sells US$51.7 Million in Common Stock
$Soleno Therapeutics(SLNO.US)$ 10% Shareholder Vivo Opportunity, LLC sold 1.1 million shares of common stock on Apr 29, 30, 2024 at an average price of $46.95 for a total value of $51.7 million. This
Soleno Therapeutics Announces Peer-Reviewed Publication Of Data Comparing DCCR Treatment To The Natural History Of Prader-Willi Syndrome
Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the publication of the co
No Data